Group B:Chemotherapy

5 trials

Sponsors

Dongfang Hospital, Beijing University of Chinese Medicine, Guangdong Provincial People's Hospital, Shanghai General Hospital, The First Hospital of China Medical University

Conditions

Extensive-stage small cell lung cancerPancreatic CancerSquamous cell lung carcinomastage IIIB-IV non-small cell lung cancer

Early Phase 1

Green Therapy of Cancer 002 (GTC002): National Key R&D Program of China: A Multicenter, Randomized Controlled Trial of Green Therapy for Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)

RecruitingITMCTR1900002370

Dongfang Hospital, Beijing University of Chinese Medicinestage IIIB-IV non-small cell lung cancer

Start: 2019-06-01Updated: 2023-02-20

Green Therapy of Cancer 002 (GTC002): National Key R&D Program of China: A Multicenter, Randomized Controlled Trial of Green Therapy for Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)

RecruitingChiCTR1900023447

Dongfang Hospital, Beijing University of Chinese Medicinestage IIIB-IV non-small cell lung cancer

Start: 2019-06-01Updated: 2019-08-27

Interventional study of DC BeadTM epirubicin in the treatment of unreactable lung squamous cell carcinoma

RecruitingChiCTR2000033037

Guangdong Provincial People's HospitalSquamous cell lung carcinoma

Start: 2020-06-01Updated: 2020-10-13

Combination of Teicilizumab and GMOEX for the Second-line Treatment of Postoperative Recurrence of Pancreatic Cancer

RecruitingChiCTR2100045916

Shanghai General HospitalPancreatic Cancer

Start: 2021-04-26Updated: 2021-12-13

Phase 2

A single-center, open-label, single-arm phase II clinical study in evaluating the efficacy and safety of Tislelizumab combined with chemotherapy and autologous NK cells in the treatment of extensive-stage small cell lung cancer

RecruitingChiCTR2100046185

The First Hospital of China Medical UniversityExtensive-stage small cell lung cancer

Start: 2021-06-01Updated: 2021-12-21